Tech Xplore

An AI approach for single-image-based 3D character animation with preserved proportions

In Proceedings of the SIGGRAPH Asia 2025 Conference Papers, a research team affiliated with UNIST reports a new AI technology ...
Multiple Sclerosis News Today

Kernal gets $48M to develop easier, cheaper CAR T-cell therapies

Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers.
Pharmabiz

Kernal Biologics receives $48 million fund from ARPA-H to develop lower cost in vivo CAR T-cell therapies for hematological cancers

Kernal Biologics Inc, a venture-backed TechBio company pioneering novel therapeutics to programme human cells directly inside the body, announced that it has been awarded up to $48 million in funding ...
precisionmedicineonline

ARPA-H Awards Kernal Bio up to $48M to Develop In Vivo CAR T-Cell Therapies

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...
MarketWatch

Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease

The MarketWatch News Department was not involved in the creation of this content. -- Funds will advance Kernal Bio's in vivo CAR T-cell therapy program and expand the capabilities of its mRNA 2.0 ...
TMCnet

Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease

Kernal Biologics, Inc., a venture-backed TechBio company pioneering novel therapeutics to program human cells directly inside the body, today announced that it has been awarded up to $48 million in ...
Morningstar

Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease

Funds will advance Kernal Bio’s in vivo CAR T-cell therapy program and expand the capabilities of its mRNA 2.0 platform Program aims to improve cancer care by increasing the accessibility of advanced ...
Business Wire

Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies

BOSTON--(BUSINESS WIRE)--Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to ...